Affiliation:
1. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX , USA
2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center , Houston, TX , USA
Abstract
Abstract
Background
Hormone receptor (HR)-positive, HER2-negative metastatic invasive lobular breast cancer (mILC) is distinct from invasive ductal cancer (IDC) in clinicopathologic and molecular characteristics, impacting its response to systemic therapy. While endocrine therapy (ET) combined with targeted therapies has shown efficacy in ET-sensitive mILC, data on chemotherapy in ET-refractory mILC remain limited. We investigated the efficacy of single-agent capecitabine (CAP) versus taxanes (TAX) in ET-refractory HR+ HER2-negative patients with mILC.
Materials and Methods
Using data from the MD Anderson prospectively collected breast cancer database, we identified patients with HR+ HER2-negative mILC who received prior ET and first-time chemotherapy in the metastatic setting. We compared outcomes between 173 CAP-treated and 96 TAX-treated patients.
Results
CAP-treated patients had significantly better median progression-free survival (PFS) than TAX-treated patients (8.8 vs 5.0 months, HR 0.63, P < .001). Overall survival (OS) did not differ significantly between the groups (42.7 vs 36.6 months for CAP vs TAX, respectively, HR 0.84, P = .241). Multivariate analyses for PFS and OS revealed better outcomes in subjects with fewer metastatic sites and those exposed to more lines of ET. Additionally, Black patients showed worse OS outcomes compared to White patients (HR 2.46; P = .001).
Conclusion
In ET-refractory HR+ HER2-negative mILC, single-agent CAP demonstrated superior PFS compared to TAX. Our findings highlight the potential benefit of CAP in this patient subset, warranting further investigation through prospective trials.
Funder
Cancer Prevention and Research Institute of Texas
NIH
NCI
Publisher
Oxford University Press (OUP)
Reference27 articles.
1. The 2019 World Health Organization classification of tumours of the breast;Tan,2020
2. Trends in incidence rates of invasive lobular and ductal breast carcinoma;Li,2003
3. Comprehensive molecular portraits of invasive lobular breast cancer;Ciriello,2015
4. Invasive lobular breast cancer: subtypes and outcome;Iorfida,2012
5. Invasive lobular carcinoma of the breast: morphology, biomarkers and’omics;Reed;Breast Cancer Res,2015